241 related articles for article (PubMed ID: 36072809)
1. The role of the bone microenvironment in regulating myeloma residual disease and treatment.
Dadzie TG; Green AC
Front Oncol; 2022; 12():999939. PubMed ID: 36072809
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
3. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma: the bone marrow microenvironment and its relation to treatment.
Andrews SW; Kabrah S; May JE; Donaldson C; Morse HR
Br J Biomed Sci; 2013; 70(3):110-20. PubMed ID: 24273897
[TBL] [Abstract][Full Text] [Related]
5. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma, immunotherapy and minimal residual disease.
Kusenda J; Kovarikova A
Neoplasma; 2016; 63(5):651-8. PubMed ID: 27468868
[TBL] [Abstract][Full Text] [Related]
7. What to do with minimal residual disease testing in myeloma.
Manasanch EE
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Microenvironment for Treating Multiple Myeloma.
Neumeister P; Schulz E; Pansy K; Szmyra M; Deutsch AJ
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886976
[TBL] [Abstract][Full Text] [Related]
9. The microenvironment in myeloma.
Lomas OC; Tahri S; Ghobrial IM
Curr Opin Oncol; 2020 Mar; 32(2):170-175. PubMed ID: 31895122
[TBL] [Abstract][Full Text] [Related]
10. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
[TBL] [Abstract][Full Text] [Related]
11. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells.
Khoo WH; Ledergor G; Weiner A; Roden DL; Terry RL; McDonald MM; Chai RC; De Veirman K; Owen KL; Opperman KS; Vandyke K; Clark JR; Seckinger A; Kovacic N; Nguyen A; Mohanty ST; Pettitt JA; Xiao Y; Corr AP; Seeliger C; Novotny M; Lasken RS; Nguyen TV; Oyajobi BO; Aftab D; Swarbrick A; Parker B; Hewett DR; Hose D; Vanderkerken K; Zannettino ACW; Amit I; Phan TG; Croucher PI
Blood; 2019 Jul; 134(1):30-43. PubMed ID: 31023703
[TBL] [Abstract][Full Text] [Related]
12. Game of Bones: How Myeloma Manipulates Its Microenvironment.
Moser-Katz T; Joseph NS; Dhodapkar MV; Lee KP; Boise LH
Front Oncol; 2020; 10():625199. PubMed ID: 33634031
[TBL] [Abstract][Full Text] [Related]
13. Myeloma bone disease: pathogenesis, current treatments and future targets.
Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
[TBL] [Abstract][Full Text] [Related]
14. Therapeutics to harness the immune microenvironment in multiple myeloma.
Ignatz-Hoover JJ; Driscoll JJ
Cancer Drug Resist; 2022; 5(3):647-661. PubMed ID: 36176763
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
16. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.
Lawson MA; McDonald MM; Kovacic N; Hua Khoo W; Terry RL; Down J; Kaplan W; Paton-Hough J; Fellows C; Pettitt JA; Neil Dear T; Van Valckenborgh E; Baldock PA; Rogers MJ; Eaton CL; Vanderkerken K; Pettit AR; Quinn JM; Zannettino AC; Phan TG; Croucher PI
Nat Commun; 2015 Dec; 6():8983. PubMed ID: 26632274
[TBL] [Abstract][Full Text] [Related]
17. The multifunctional role of Notch signaling in multiple myeloma.
Sabol HM; Delgado-Calle J
J Cancer Metastasis Treat; 2021; 7():. PubMed ID: 34778567
[TBL] [Abstract][Full Text] [Related]
18. Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma.
Papadimitriou K; Tsakirakis N; Malandrakis P; Vitsos P; Metousis A; Orologas-Stavrou N; Ntanasis-Stathopoulos I; Kanellias N; Eleutherakis-Papaiakovou E; Pothos P; Fotiou D; Gavriatopoulou M; Kastritis E; Dimopoulos MA; Terpos E; Tsitsilonis OE; Kostopoulos IV
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33158030
[TBL] [Abstract][Full Text] [Related]
19. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
20. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
